Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION: Pegaptanib in Neovascular AMD
NCT00021736Phase 3Completed
- Sponsor
- OSI Eyetech
- Start
- Jul 2001
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 3 trial of pegaptanib sodium in exudative age-related macular degeneration, sponsored by OSI Eyetech. Started Jul 2001; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT00021736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021736.